Gossamer Bio (GOSS) Other Non-Current Assets (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Other Non-Current Assets of $398000.0 for Q1 2026, up 28.39% year-over-year from $310000.0 in Q1 2025, and down 2.45% quarter-over-quarter from $408000.0 in Q4 2025.
Gossamer Bio (GOSS) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Gossamer Bio's Other Non-Current Assets history runs 9 years deep, the most recent figure standing at $398000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 28.39% year-over-year to $398000.0; the TTM figure through Mar 2026 stood at $398000.0 (up 28.39% YoY), while the FY2025 annual figure was $408000.0, up 44.17% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $398000.0, down from $408000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.3 million in Q2 2022, with the low at $59000.0 in Q2 2024.
- The 5-year median for Other Non-Current Assets is $613000.0 (2024), against an average of $559176.5.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets tumbled 92.34% in 2024, then jumped 549.15% in 2025.
- Gossamer Bio's Other Non-Current Assets stood at $680000.0 in 2022, then fell by 9.12% to $618000.0 in 2023, then plunged by 54.21% to $283000.0 in 2024, then surged by 44.17% to $408000.0 in 2025, then dropped by 2.45% to $398000.0 in 2026.
- Business Quant data shows GOSS's Other Non-Current Assets at $398000.0 in Q1 2026, $408000.0 in Q4 2025, and $407000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | 429,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 429,000.00 |
| Mar 31, 2026 | 398,000.00 |
| Dec 31, 2025 | 408,000.00 |
| Sep 30, 2025 | 407,000.00 |
| Jun 30, 2025 | 383,000.00 |
| Mar 31, 2025 | 310,000.00 |
| Dec 31, 2024 | 283,000.00 |
| Sep 30, 2024 | 283,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Mar 31, 2024 | 613,000.00 |
| Dec 31, 2023 | 618,000.00 |
| Sep 30, 2023 | 649,000.00 |
| Jun 30, 2023 | 770,000.00 |
| Mar 31, 2023 | 743,000.00 |
| Dec 31, 2022 | 680,000.00 |
| Sep 30, 2022 | 629,000.00 |
| Jun 30, 2022 | 1.25 Mn |
| Mar 31, 2022 | 1.02 Mn |
| Dec 31, 2021 | 1.08 Mn |
| Sep 30, 2021 | 1.11 Mn |